Skip to content
lifestyle.toptraveltrends.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IGC Pharma, Inc.
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
November 9, 2026
IGC Pharma’s Alzheimer’s Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
November 5, 2026
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
September 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
August 18, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
August 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
July 29, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
June 9, 2026
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
June 2, 2026
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
May 19, 2026
1
2
Next Page
→